Inspire Medical corrects Q2 2026 results date to Aug. 3
Inspire Medical Systems (NYSE: INSP) has corrected the date for its second-quarter 2026 financial results release to Monday, August 3, 2026, after market close. The company will host a conference call at 5:00 p.m. Eastern Time on the same day to discuss the results and business developments. Investors can access the call via webcast or register to ask questions, with a replay available for two weeks afterward.
Inspire Medical Systems, Inc. to Report Second Quarter 2026 Financial Results on July 6, 2026
Inspire Medical Systems, Inc. will release its second-quarter 2026 financial results after market close on Monday, August 3. The company's management will host a conference call at 5:00 p.m. Eastern Time to discuss these results and recent business developments. A webcast of the call will be available on the Investor Relations page of the Inspire website.
Inspire Medical sets Aug. 3 earnings call after Q2 results
Inspire Medical Systems (NYSE: INSP) will release its second quarter 2026 financial results after the market close on Monday, August 3, 2026. The company will host a conference call at 5:00 p.m. Eastern Time on the same day to discuss the results and recent business developments. Investors can access the call via webcast or by registering for a unique access code if they plan to ask questions.
Inspire Medical Systems (INSP) Gets a Hold from Wells Fargo
Wells Fargo analyst Larry Biegelsen maintained a Hold rating for Inspire Medical Systems (INSP) with a price target of $56.00, while the company's shares closed at $46.95. This follows a similar Hold rating from Evercore ISI, though Freedom Capital Markets initiated coverage with a Buy rating. The company reported $204.58 million in revenue and a GAAP net loss of $11.29 million for the quarter ending March 31, with corporate insider sentiment leaning negative due to recent share sales.
Wells Fargo Maintains Inspire Medical Systems(INSP.US) With Hold Rating, Maintains Target Price $56
Wells Fargo has reaffirmed its "Hold" rating for Inspire Medical Systems (INSP.US) and maintained its target price at $56. This indicates a neutral outlook on the stock's future performance based on the bank's analysis.
Inspire Medical Systems (NASDAQ: INSP) D.E. Shaw affiliate reports 5.1% holding
D. E. Shaw & Co., L.P. and its affiliates have reported a 5.1% beneficial ownership stake in Inspire Medical Systems (NASDAQ: INSP), totaling 1,483,107 shares of common stock. The Schedule 13G filing indicates shared voting power over 1,374,263 shares and shared dispositive power over all 1,483,107 shares. Despite being listed as a reporting person, David E. Shaw disclaims beneficial ownership, clarifying that the holdings are managed through various affiliated entities.
INSP - Inspire Medical Systems Inc Options
This article provides a detailed financial overview of Inspire Medical Systems Inc (INSP), including its last closing price, market capitalization, income, sales, and various financial ratios. It also lists key performance indicators, analyst recommendations, and insider/institutional ownership details. The data suggests a company with significant sales growth in the past but facing challenges in EPS projections and long-term stock performance.
INSP Initiates Coverage On Inspire Medical Systems -- Rating Buy
Freedom Capital Markets initiated coverage on Inspire Medical Systems (INSP) with a "Buy" rating and a price target of $62.00, suggesting a significant upside from its current trading price of $44.61. The company is considered undervalued according to GuruFocus's GF Value™ and shows strong financial strength, despite some challenges in profitability and momentum. Investors should weigh the positive analyst rating and undervaluation against mixed signals from insider activity and GF Score™ metrics.
Inspire Medical shares initiated at buy by Freedom Capital on valuation
Freedom Capital has initiated coverage on Inspire Medical Systems Inc. (NYSE:INSP) with a "buy" rating and a price target of $62.00, suggesting a 39% upside from its current price. Despite potential near-term volatility from reimbursement issues and competition, the firm believes these challenges are already priced in, making it an attractive entry point. The company maintains a strong balance sheet and is expected to continue leading the obstructive sleep apnea market, though other analysts have recently downgraded the stock due to coding and reimbursement concerns.
Inspire Medical Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Inspire Medical Systems, Inc. - INSP
Kahn Swick & Foti, LLC (KSF) is continuing its investigation into Inspire Medical Systems, Inc. (NYSE: INSP) following a significant reduction in the company's 2025 earnings guidance and a securities class action lawsuit. The investigation focuses on whether Inspire's officers and directors breached their fiduciary duties after the delayed launch of its Inspire V device, attributed to undisclosed issues like incomplete training, software problems, and excess inventory. KSF encourages long-term Inspire shareholders with relevant information to contact them for legal consultation.
Inspire Medical Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Inspire Medical Systems, Inc. - INSP
Kahn Swick & Foti, LLC (KSF) is continuing its investigation into Inspire Medical Systems, Inc. (NYSE: INSP) and its officers and directors. This follows a previous securities class action lawsuit against the company after it disclosed an "elongated timeframe" for its Inspire V device launch due to undisclosed issues and subsequently slashed its 2025 earnings guidance by over 80%. KSF is investigating whether fiduciary duties were breached and invites long-term shareholders to contact them to discuss their legal rights.
Inspire Medical Systems, Inc.(NYSE: INSP) added to Russell 2000 Index
Inspire Medical Systems, Inc. (NYSE: INSP) has been added to the Russell 2000 Index, as well as the Russell 2000 Value and Russell 2000 Growth Benchmarks. Simultaneously, the company was dropped from several other Russell indices, including the Russell Midcap Growth, Russell 1000 Dynamic, Russell 1000 Growth, Russell Midcap, and Russell 1000 Indices. Inspire Medical Systems is a medical technology company focused on solutions for obstructive sleep apnea (OSA).
Inspire Medical Systems, Inc.(NYSE:INSP) dropped from Russell Midcap Growth Benchmark
Inspire Medical Systems, Inc. (NYSE:INSP) has been dropped from the Russell Midcap Growth Benchmark. This news comes alongside several other index changes for the company, including being added to the Russell 2000 Index, Russell 2000 Value Benchmark, and Russell 2000 Growth Benchmark, while also being dropped from other Russell indices like the 1000 Dynamic and 1000 Growth. Inspire Medical Systems is a medical technology company specializing in solutions for obstructive sleep apnea.
Why Inspire Medical Systems (INSP) Is Up 10.6% After Russell Index Reclassification To Small Cap
Inspire Medical Systems (INSP) saw its stock rise by 10.6% after being reclassified from the Russell 1000 to smaller-cap Russell indices like the Russell 2000. This shift may alter its investor base and position sizing, though the underlying investment narrative for its obstructive sleep apnea therapy remains. The company faces challenges including slower growth and execution risks for its Inspire V system, with analysts projecting a revenue of $987.4 million and earnings of $67.1 million by 2029.
Why Inspire Medical Systems (INSP) Is Up 10.6% After Russell Index Reclassification To Small Cap
Inspire Medical Systems (INSP) saw a 10.6% increase after being reclassified from the Russell 1000 to smaller-cap and value-oriented Russell indices in late June 2026. This reclassification could shift the company's investor base and position sizing, influencing its investment narrative amidst ongoing challenges like slower growth and execution risks with its Inspire V rollout. Despite these hurdles, data from SLEEP 2026 suggests the new system could sustain physician confidence and payer support, with analysts projecting $987.4 million revenue and $67.1 million earnings by 2029 for Inspire, while some bearish analysts project lower figures.
Inspire Medical Systems | SCHEDULE 13G: Others
This article consists solely of the word "Document" and appears to be an incomplete or placeholder entry related to a SCHEDULE 13G filing for Inspire Medical Systems. Without further content, the specific details or implications of this filing cannot be determined.
Inspire Medical Systems Inc at Wells Fargo MedTech Innovation Spotlight Transcript
This article provides the transcript from Inspire Medical Systems Inc.'s appearance at the Wells Fargo MedTech Innovation Spotlight. The discussion features Chairman and CEO Tim Herbert, CFO Matt Osberg, and VP of Investor Relations Ezgi Yagci, covering topics such as Inspire V, coding and reimbursement, clinical data, competitive market dynamics, and the company's outlook. The event began with a short presentation by Tim Herbert, followed by a Q&A session.
Inspire Medical Systems (INSP) Wells Fargo 2026 MedTech Innovation Spotlight Summary
This article summarizes Inspire Medical Systems' (INSP) presentation at the Wells Fargo 2026 MedTech Innovation Spotlight. Key updates include established clear coding pathways for reimbursement, advancements in technology with the Inspire V system and Inspire VI in development, and strong clinical evidence from the ADHERE registry showcasing reduced Apnea-Hypopnea Index and improved cardiovascular health. The company continues to focus on improving therapy adherence and streamlining administrative processes.
INSP: Inspire V advances clinical outcomes and reimbursement clarity, supporting growth in sleep apnea care
Inspire V has established clear coding and reimbursement pathways, demonstrating improved clinical outcomes and high patient adherence for sleep apnea treatment. New data also suggests a link between this therapy and reduced cardiovascular risk. These advancements, coupled with ongoing innovation and market education, are expected to support future growth for Inspire Medical Systems, Inc.
Inspire Medical Systems (INSP) shares June 26, 2026 investor presentation via 8-K
Inspire Medical Systems (INSP) filed an 8-K to announce its participation in investor and analyst meetings in June 2026, where it will use a formal investor presentation. This presentation (Exhibit 99.1) is available on the company's investor relations website and is furnished under Regulation FD for informational purposes. The filing emphasizes that the presentation is not considered "filed" for Section 18 of the Securities Exchange Act of 1934 and is not automatically incorporated into other SEC filings.
Inspire Medical Systems, Inc. Actuals & Estimates (NYSE:INSP)
This article provides financial actuals and estimates for Inspire Medical Systems, Inc. (NYSE:INSP), including its current stock price, volatility, market capitalization, earnings, and revenue. It also includes analyst forecasts for the stock's future price, the company's historical highs and lows, and upcoming earnings report dates. The company's recent performance shows a 5.22% increase in the past 24 hours, but a 65.15% decrease over the last year.
INSP Highlights New OSA Data and PREDICTOR Study at SLEEP 2026
Inspire Medical Systems (INSP) presented new clinical data, technology advancements, and cardiovascular outcomes research at SLEEP 2026, focusing on their Inspire therapy for obstructive sleep apnea (OSA). Key highlights included the next-generation Inspire V system, positive outcomes from the PREDICTOR study, and data showing lower rates of cardiovascular events compared to CPAP therapy. Despite a recent stock decline, these presentations are expected to strengthen Inspire Medical's position in the sleep apnea treatment market, which is projected to grow significantly.
Assessing Inspire Medical Systems (INSP) Valuation After A Prolonged Share Price Slide
Inspire Medical Systems (INSP) has experienced a significant share price decline recently, though a narrative from Simply Wall St suggests it is currently undervalued at $52.17 per share. This valuation is based on expectations that current operational delays are transitory and future growth will reaccelerate. The article encourages investors to assess the company's risks and potential upside using additional resources and to broaden their watchlist.
Is New Cardiovascular Data From SLEEP 2026 Altering The Investment Case For Inspire Medical Systems (INSP)?
New clinical data presented by Inspire Medical Systems at SLEEP 2026 suggests that their hypoglossal nerve stimulation therapy may improve cardiovascular outcomes for obstructive sleep apnea patients more than CPAP or no treatment. This positive finding could strengthen the investment case for INSP by potentially reinforcing procedure volumes and reimbursement, which are crucial for growth and margins. However, investors still need to consider ongoing reimbursement and adoption risks as payers might push for cheaper, less invasive alternatives.
Inspire Medical Systems (INSP) Stock Could Be 18.3% Undervalued After SLEEP 2026 Data
Inspire Medical Systems (INSP) presented new clinical data at the SLEEP 2026 conference, yet its stock has seen mixed short-term momentum and a significant multi-year decline. Despite a current valuation labeling it 18.3% undervalued at $42.61 against a fair value of $52.17, the company faces risks related to reimbursement and reliance on the Inspire V rollout. Investors are encouraged to review the company's rewards and warning signs before making investment decisions.
Inspire Medical Systems, Inc. Announces Presence at SLEEP 2026 and Publication of PREDICTOR Study
Inspire Medical Systems (NYSE: INSP) announced its participation in SLEEP 2026, where it will showcase its Inspire V system and new clinical data. The company is highlighting research showing the effectiveness of Inspire therapy in reducing hypoxic burden and improving cardiovascular outcomes for patients with obstructive sleep apnea (OSA). Additionally, Inspire announced the publication of the PREDICTOR study, which identifies BMI and neck circumference as potential predictors for therapy eligibility, potentially streamlining diagnosis.
Inspire Medical Systems, Inc. Announces Presence at SLEEP 2026 and Publication of PREDICTOR Study
Inspire Medical Systems, Inc. announced its participation in SLEEP 2026, highlighting new clinical data, technology advancements, and cardiovascular outcomes research related to its Inspire V system for obstructive sleep apnea (OSA). The company emphasized the system's effectiveness, improvements in cardiovascular risk markers, and the publication of the PREDICTOR study, which identifies predictors for screening Inspire therapy eligibility without drug-induced sleep endoscopy. Multiple presentations and poster sessions at SLEEP 2026 will further detail the benefits of Inspire therapy, including its impact on hypoxic burden, cardiovascular outcomes, and superior patient adherence compared to CPAP.
Inspire Medical data highlights cardiovascular outcomes with neuromod for sleep apnea
Inspire Medical announced new data from its Inspire V implantable neuromodulation system for obstructive sleep apnea (OSA) presented at the SLEEP meeting. The findings highlight improved cardiovascular risk markers, recent technology advancements with Inspire V, and clinical evidence supporting closed-loop therapy. The company also presented data suggesting that body mass index and neck circumference can predict complete concentric collapse, potentially reducing the need for drug-induced sleep endoscopy in screening for Inspire therapy eligibility.
Inspire Medical Systems, Inc. Announces Presence at SLEEP 2026 and Publication of PREDICTOR Study
Inspire Medical Systems, Inc. announced its participation in SLEEP 2026, highlighting new clinical data, technology advancements, and cardiovascular outcomes research for its Inspire therapy for obstructive sleep apnea (OSA). The company showcased the Inspire V system and presented findings from the STAR trial, which demonstrated significant reductions in hypoxic burden and improvements in sleepiness. Additionally, Inspire announced the publication of the PREDICTOR study, identifying anthropometric measurements as potential predictors of complete concentric collapse to streamline patient eligibility screening.
Inspire sleep apnea implant linked to fewer heart, stroke events
Inspire Medical Systems announced its participation in SLEEP 2026 and the publication of the PREDICTOR study, highlighting new clinical data on its Inspire V system and cardiovascular outcomes. Research indicates that Inspire therapy significantly reduces hypoxic burden and the odds of major adverse cardiovascular events (MACE) compared to CPAP and untreated populations. The PREDICTOR study also suggests that patient screening for Inspire therapy may be streamlined without drug-induced sleep endoscopy, potentially reducing diagnostic burdens and costs.
Inspire Medical Systems, Inc. Announces Presence At SLEEP 2026 And Highlights New Clinical Data, Technology Advancements, And Cardiovascular Outcomes Research
Inspire Medical Systems, Inc. will participate in SLEEP 2026 to showcase its Inspire V system and recent technological advancements, including closed-loop therapy and the Inspire SleepSync platform. The company will highlight new clinical data supporting the therapy's effectiveness, particularly in reducing hypoxic burden and improving cardiovascular outcomes compared to CPAP and untreated patients. They will also present findings from the PREDICTOR study, suggesting that certain patients may be screened for Inspire therapy eligibility without requiring drug-induced sleep endoscopy.
INSP Technical Analysis & Stock Price Forecast
This article provides a technical analysis and stock price forecast for Inspire Medical Systems Inc (INSP). As of June 12, 2026, the overall technical sentiment for INSP is Neutral, with a mix of buy and sell signals from various indicators. Key metrics like RSI, MACD, and moving averages are detailed, along with significant support and resistance levels.
Inspire Medical Systems, Inc. to Participate in the Wells Fargo 2026 MedTech Innovation Spotlight
Inspire Medical Systems, Inc. announced its management team will participate in the Wells Fargo 2026 MedTech Innovation Spotlight on Friday, June 26, 2026, at 10:00 a.m. Eastern Time. The presentation will be available via a live webcast and a replay for two weeks on Inspire’s Investor website. Inspire specializes in innovative, minimally invasive solutions for obstructive sleep apnea.
Inspire Medical to discuss sleep apnea tech at Wells Fargo MedTech event
Inspire Medical Systems (NYSE: INSP) announced its participation in the Wells Fargo 2026 MedTech Innovation Spotlight on Friday, June 26, 2026. The company's management team will present at 10:00 a.m. Eastern Time, with a live webcast and a two-week replay available for investors. The discussion will focus on their minimally invasive solutions for obstructive sleep apnea.
Inspire Medical Systems, Inc. to Participate in the Wells Fargo 2026 MedTech Innovation Spotlight
Inspire Medical Systems, Inc. announced that its management team will participate in the Wells Fargo 2026 MedTech Innovation Spotlight on Friday, June 26, 2026, speaking at 10:00 a.m. Eastern Time. A live webcast and subsequent replay of the presentation will be available on Inspire's investor website. The company specializes in developing minimally invasive solutions for obstructive sleep apnea.
Alphatec vs. Inspire Medical Systems: Investment Profiles in Medical Devices - News and Statistics
This article compares the investment profiles of two medical device companies, Alphatec and Inspire Medical Systems, highlighting their distinct market focuses and financial health. Alphatec specializes in spine surgery with reported 25% revenue growth in fiscal year 2025 but still recorded a significant net loss and high debt-to-equity ratio. Inspire Medical Systems focuses on neurostimulation therapy for sleep apnea, addressing an underserved patient population and establishing a leading position in advanced respiratory care.
Assessing Inspire Medical Systems (INSP) Valuation After A Prolonged Share Price Slide
Inspire Medical Systems (INSP) has seen its stock slide significantly, down 69.1% over the past year, despite a recent 4.0% gain. Simply Wall St indicates the company's fair value at $52.17 per share, suggesting it is currently undervalued compared to its last close of $42.21, due to transitory issues that are expected to resolve and reaccelerate procedure volumes and revenue growth in 2026. The article advises investors to consider the potential upside against ongoing concerns like the Inspire V rollout and reimbursement uncertainties.
Assessing Inspire Medical Systems (INSP) Valuation After A Prolonged Share Price Slide
Inspire Medical Systems (INSP) stock has seen a significant decline over the past year, prompting questions about its current valuation. Despite a recent short-term gain, the shares are down substantially, leading some to consider if the company is undervalued. A popular narrative suggests a fair value of $52.17 per share, indicating it is currently undervalued, with recent operational delays considered transitory.
Inspire Medical Systems, Inc. (INSP) Stock Analysis: Navigating the Healthcare Sector with a 26.65% Potential Upside
Inspire Medical Systems, Inc. (INSP) is a prominent healthcare company specializing in innovative solutions for obstructive sleep apnea (OSA) with its flagship neurostimulation device. Despite a recent modest dip, the stock, currently valued at $41.19, shows potential for future growth with a 26.65% upside according to analysts' average target price. The company's strong financial health, indicated by an 18.37% return on equity and substantial free cash flow, supports its growth-oriented strategy of reinvesting profits.
Why is Inspire (INSP) down 15.9% since last earnings report?
This article analyzes why Inspire (INSP) stock has dropped 15.9% since its last earnings report. It likely delves into the financial results, market reactions, and other factors contributing to the decline. The content is missing, preventing a full summary.
Inspire Medical Systems Hits 52-Week Low at $39.29 Amidst Major Decline
Inspire Medical Systems, a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 39.29 as of June 2, 2026, marking a significant performance decline of 74.79% over the past year. Despite a market capitalization of USD 1,683 million and a return on equity of 19.13%, the company's stock has consistently underperformed market benchmarks. Its previous 52-week high was USD 146.50, highlighting the severe drop.
Inspire Medical Systems stock hits 52-week low at 39.51 USD By Investing.com
Inspire Medical Systems stock has fallen to a new 52-week low of $39.51, representing a 70.48% decline over the past year. Despite this, InvestingPro analysis indicates the stock may be undervalued, holding more cash than debt, and is predicted to be profitable this year. However, recent analyst downgrades and revised price targets reflect concerns over expected sales growth and reimbursement challenges, despite the company exceeding Q1 2026 earnings and revenue forecasts.
INSP: CMS Coding Progress Will Gradually Support Future Reimbursement And Earnings Power
Inspire Medical Systems (INSP) is facing challenges with reimbursement and coding uncertainty, leading analysts to cut its blended price target from $79 to $52. Bullish analysts see the recent CMS update as a positive for hospital reimbursement, while bearish analysts are concerned about the lack of a permanent coding for Inspire V and new MAC billing changes impacting procedure volumes. The company revised its 2026 revenue outlook to $825M-$875M and EPS to $0.07-$0.62, and stockholders approved declassifying the board.
Inspire Medical Systems stock hits 52-week low at 39.51 USD
Inspire Medical Systems (INSP) stock plunged to a new 52-week low of $39.51, reflecting a 70.48% drop over the past year despite being considered undervalued by InvestingPro. The company's financial health is rated "GREAT" with more cash than debt, and analysts predict profitability this year. However, recent downgrades and reduced price targets from BofA Securities, Stifel, and Mizuho followed a weaker-than-expected 2026 guidance, despite Q1 2026 earnings exceeding expectations.
Inspire Medical Systems stock hits 52-week low at 39.51 USD
Inspire Medical Systems (INSP) stock has dropped to a 52-week low of $39.51, representing a 70.48% decline over the past year, despite analysts predicting profitability and the company maintaining a "GREAT" financial health score with more cash than debt. The company recently reported better-than-expected Q1 2026 earnings and revenue, but several analysts have downgraded their ratings or cut price targets due to concerns over coding pathways, reimbursement challenges, and weaker-than-expected 2026 guidance. InvestingPro suggests the stock is currently undervalued, indicating potential upside for investors.
Can Inspire Medical Systems (INSP) Convert Revenue Beats Into Sustainable Earnings Strength?
Inspire Medical Systems recently reported mixed quarterly results, with revenue exceeding expectations but full-year EPS guidance being missed. The company faces challenges from slower growth, reimbursement pressures, and cost inflation, leading to a reset in 2026 revenue and EPS guidance. Despite these near-term challenges, the long-term forecast projects significant revenue and earnings growth by 2029, suggesting a substantial upside to its current price if execution on Inspire V adoption and reimbursement clarity are successful.
Can Inspire Medical Systems (INSP) Convert Revenue Beats Into Sustainable Earnings Strength?
Inspire Medical Systems (INSP) recently reported Q1 results with revenue up 1.6% year-on-year, beating analyst expectations, but missed full-year EPS guidance. The company's investment narrative now focuses on execution for Inspire V adoption and reimbursement clarity, amidst revised lower revenue and EPS guidance for 2026 due to cost inflation and reimbursement pressures. While the positive revenue suggests potential, the softer earnings outlook and ongoing uncertainties could prompt analysts to reassess their growth assumptions.
Cash Machine Trading Cheap – Inspire Medical Systems Stock Set to Run?
Inspire Medical Systems (INSP) stock is highlighted as a potential opportunity due to its strong fundamentals, including an 8.1% cash flow yield and 8.9% revenue growth. The stock is currently trading at a significant discount (37% below its 3-month high, 71% below its 1-year high, and 81% below its 2-year high) compared to S&P medians. While INSP shows promise, the article also advises considering the inherent risks of single stock trading and suggests alternative high-quality stocks like Intuit, HCA Healthcare, and Boston Scientific.
Soleus files 1.47M-share stake in Inspire Medical Systems (INSP)
Soleus Capital Master Fund and its affiliates have reported a beneficial ownership of 1,470,748 shares in Inspire Medical Systems (INSP), which represents 5.1% of the company's outstanding common stock. This disclosure was made via a SCHEDULE 13G SEC filing, indicating a passive investment. The percentage is based on 28,813,153 shares outstanding as of April 28, 2026, and Guy Levy disclaims beneficial ownership for purposes other than Section 13(d) reporting.
What Does Stifel Think About Inspire Medical (INSP) After a Guidance Cut That Surprised Wall Street?
Stifel analyst Jonathan Block maintained a Buy rating on Inspire Medical Systems (INSP) but lowered the price target to $65 after the company cut its full-year 2026 revenue guidance. The reduced guidance, attributing to new billing codes for its sleep apnea device, surprised Wall Street, with Stifel's previous estimate already being the lowest. Despite the setback, Block believes Inspire's market dominance will hold, and reimbursement clarity is expected to improve.
